Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial

PURPOSE: We evaluated study outcomes in patients enrolled in Asian regions in the phase III EMBRACA trial of talazoparib vs. chemotherapy. MATERIALS AND METHODS: Patients with human epidermal growth factor receptor 2–negative germline BRCA1/2-mutated advanced breast cancer who received prior chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kyung-Hun, Sohn, Joohyuk, Goodwin, Annabel, Usari, Tiziana, Lanzalone, Silvana, Im, Seock-Ah, Kim, Sung-Bae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524025/
https://www.ncbi.nlm.nih.gov/pubmed/33781053
http://dx.doi.org/10.4143/crt.2020.1381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524025/
https://www.ncbi.nlm.nih.gov/pubmed/33781053
http://dx.doi.org/10.4143/crt.2020.1381

Ejemplares similares